IFG Advisory LLC purchased a new stake in Merck & Co., Inc. (NYSE:MRK) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 12,510 shares of the company’s stock, valued at approximately $1,134,000.
A number of other institutional investors and hedge funds have also bought and sold shares of the business. Krilogy Financial LLC grew its holdings in Merck & Co., Inc. by 0.4% in the 2nd quarter. Krilogy Financial LLC now owns 3,129 shares of the company’s stock valued at $201,000 after buying an additional 11 shares during the period. Balentine LLC grew its holdings in shares of Merck & Co., Inc. by 1.0% during the 2nd quarter. Balentine LLC now owns 2,107 shares of the company’s stock worth $135,000 after purchasing an additional 20 shares during the period. Jackson Grant Investment Advisers Inc. grew its holdings in shares of Merck & Co., Inc. by 0.4% during the 2nd quarter. Jackson Grant Investment Advisers Inc. now owns 9,291 shares of the company’s stock worth $595,000 after purchasing an additional 39 shares during the period. Thompson Davis & CO. Inc. grew its holdings in shares of Merck & Co., Inc. by 0.9% during the 2nd quarter. Thompson Davis & CO. Inc. now owns 4,313 shares of the company’s stock worth $276,000 after purchasing an additional 40 shares during the period. Finally, Cornerstone Advisory LLP grew its holdings in shares of Merck & Co., Inc. by 0.4% during the 2nd quarter. Cornerstone Advisory LLP now owns 11,110 shares of the company’s stock worth $712,000 after purchasing an additional 43 shares during the period. Institutional investors own 74.79% of the company’s stock.
MRK has been the subject of a number of research reports. Bank of America initiated coverage on Merck & Co., Inc. in a report on Tuesday, November 28th. They set a “buy” rating and a $64.00 target price for the company. SunTrust Banks upgraded Merck & Co., Inc. from a “hold” rating to a “buy” rating and boosted their target price for the stock from $54.00 to $72.00 in a report on Tuesday, January 16th. Sanford C. Bernstein reiterated a “buy” rating and set a $64.00 target price on shares of Merck & Co., Inc. in a report on Wednesday, November 15th. BMO Capital Markets set a $68.00 target price on Merck & Co., Inc. and gave the stock a “buy” rating in a report on Wednesday, December 13th. Finally, ValuEngine upgraded Merck & Co., Inc. from a “hold” rating to a “buy” rating in a report on Wednesday, January 10th. One analyst has rated the stock with a sell rating, ten have issued a hold rating and twelve have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $66.41.
Merck & Co., Inc. (NYSE:MRK) opened at $55.36 on Tuesday. The firm has a market capitalization of $148,667.91, a P/E ratio of 13.85, a price-to-earnings-growth ratio of 2.27 and a beta of 0.81. Merck & Co., Inc. has a fifty-two week low of $53.12 and a fifty-two week high of $66.41. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.33 and a quick ratio of 1.06.
Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Friday, February 2nd. The company reported $0.98 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.94 by $0.04. The firm had revenue of $10.43 billion during the quarter, compared to analysts’ expectations of $10.48 billion. Merck & Co., Inc. had a return on equity of 28.61% and a net margin of 6.40%. Merck & Co., Inc.’s quarterly revenue was up 3.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.89 EPS. equities analysts forecast that Merck & Co., Inc. will post 4.16 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Friday, April 6th. Shareholders of record on Thursday, March 15th will be issued a $0.48 dividend. This represents a $1.92 dividend on an annualized basis and a yield of 3.47%. The ex-dividend date is Wednesday, March 14th. Merck & Co., Inc.’s dividend payout ratio is presently 206.45%.
Merck & Co., Inc. declared that its board has authorized a share buyback program on Tuesday, November 28th that authorizes the company to repurchase $10.00 billion in shares. This repurchase authorization authorizes the company to reacquire shares of its stock through open market purchases. Stock repurchase programs are generally an indication that the company’s leadership believes its shares are undervalued.
ILLEGAL ACTIVITY NOTICE: “IFG Advisory LLC Purchases Shares of 12,510 Merck & Co., Inc. (MRK)” was published by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/03/13/ifg-advisory-llc-purchases-shares-of-12510-merck-co-inc-mrk.html.
About Merck & Co., Inc.
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.